Verastem Expects $30.9M Revenue for 2025

By Chris Stiles • Wednesday, February 04 11:46 • Permanent Link

Verastem Oncology (NASDAQ: VSTM) has released its preliminary unaudited results for the fourth quarter of 2025 and the full year 2025. The company expects Avmapki™ Fakzynja™ co-pack net product revenues to be approximately $17.5 million for Q4 2025 and approximately $30.9 million for the full year 2025, following U.S. FDA approval in May 2025.

As of December 31, 2025, the company had preliminary unaudited cash, cash equivalents, and investments of $205 million. On a pro forma basis, including the net proceeds from the exercise of expiring cash warrants, the cash, cash equivalents, and investments were $234 million. The company expects its cash runway to extend into the first half of 2027.

Verastem Oncology's leadership is set to participate in a fireside chat at the Guggenheim Emerging Outlook Conference in New York City on February 11, 2026.

In 2026, the company plans to focus on maximizing the commercial launch of Avmapki Fakzynja co-pack while advancing its pipeline targeting RAS/MAPK pathway-driven cancers to create sustainable long-term growth.

For Avmapki Fakzynja co-pack, the company expects to report a topline readout of the primary endpoint in the RAMP 301 trial in mid-2027 and continue to pursue regulatory paths for potential expansion of the product launch into Europe and Japan.

The company also provided an update on its VS-7375 program, an investigational, highly selective and oral KRAS G12D (on/off) inhibitor, stating that it plans to report an interim update on the phase 1/2 trial in the first half of 2026 and engage with the FDA in the same period to discuss its development path forward, including potential registration-directed clinical trials in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).

Verastem Oncology also expects to report an update on the safety and efficacy of the RAMP 205 expansion cohort with at least six months of follow-up on all patients in Q2 2026.

These figures and strategic priorities demonstrate the company's commitment to advancing new medicines for patients with RAS/MAPK pathway-driven cancers. As a result of these announcements, the company's shares have moved 1.21% on the market, and are now trading at a price of $6.68. For the full picture, make sure to review Verastem's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.